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Abstract
Aims/hypothesis The phytoestrogen enterolactone is a gut microbiota-derived metabolite of plant lignans with suggested ben-
eficial properties for health. In the current study, we investigated the association between pre-diagnostic plasma enterolactone
concentrations and mortality among individuals diagnosed with type 2 diabetes.
Methods In a population of people diagnosed with diabetes, nested within the Danish Diet, Cancer and Health cohort,
we conducted a case-cohort study including a random sample of n = 450 cases (deceased) and a randomly selected
subcohort of n = 850 (in total n = 617 deaths). Information on diagnosis, vital status and cause of death was obtained
from Danish registers. Cox proportional hazard models with special weighting were applied to assess all-cause and
cause-specific mortality.
Results The median enterolactone concentration of the current population was low, 10.9 nmol/l (5th percentile to 95th percentile:
1.3–59.6), compared with previously reported concentrations from the Diet, Cancer and Health cohort. Pre-diagnostic
enterolactone concentrations were associated with lower all-cause mortality when assessed linearly per doubling in concentration
(log2) (HR 0.91 [95% CI 0.85, 0.96]) and according to quartiles (HR 0.63 [95% CI 0.48, 0.84]) for the highest quartile of
enterolactone compared with the lowest quartile. For cause-specific mortality, only death from diabetes (registered as underlying
cause of death) reached statistical significance.
Conclusions/interpretation Based on this large cohort of people with diabetes with detailed and complete baseline and follow-up
information, pre-diagnostic enterolactone concentrations were inversely associated with mortality. To our knowledge, this is the
first study on enterolactone and type 2 diabetes mortality. Our findings call for further exploration of enterolactone in type 2
diabetes management.
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Introduction
Dietary factors, such as whole-grain intake, have been related
to a lower mortality from type 2 diabetes [1], and soluble fibre
has been shown to reduce HbA1c and fasting plasma glucose
in individuals diagnosed with type 2 diabetes [2].
Furthermore, among people with type 2 diabetes, high LDL-
cholesterol has been associated with higher risk of cardiovas-
cular mortality, which is a common cause of premature death
in type 2 diabetes [3]. Although further investigations are
required, dietary interventions with whole-grain rye [4] and
flaxseed [5] have indicated beneficial effects on LDL-choles-
terol. Thus, diet plays a role in the management of type 2
diabetes and good management may improve survival rate.
Enterolactone, a phytoestrogen metabolite produced by the
gut microbiota after ingestion of dietary lignans, has been stud-
ied widely for its protective effects in chronic disease [6]. The
main dietary sources include seeds, whole grains, nuts and
fibre-rich fruits and vegetables, with smaller amounts found
in coffee, tea, wine and beer [7]. The metabolism of lignans
into enterolignans (enterodiol and enterolactone) is affected by
several factors including smoking, obesity, dietary sources of
lignans [6], gut microbiota [8] and use of antibiotics [9].
The role of enterolactone in type 2 diabetes management
remains unstudied in observational investigations but inter-
vention studies suggest favourable associations between
lignan intake and several factors associated with management
of type 2 diabetes: glycaemic control, inflammatory markers
and cholesterols [10–12]. The observed associations related to
factors of importance for diabetes management call for further
investigation into whether enterolactone may be a protective
factor for mortality among people with diabetes. Therefore,
the aim of the present study was to investigate prospectively
the association between pre-diagnostic plasma enterolactone
concentrations and mortality rate ratio among people diag-
nosed with type 2 diabetes in the Diet, Cancer and Health
cohort [13]. The association was examined for all-cause mor-
tality as the primary outcome and secondarily for cause-
specific mortality. The hypothesis was that high plasma
enterolactone concentrations are associated with lower mor-
tality risk (rate ratio) compared with low concentrations.
Methods
Study population and follow-up The Danish Diet, Cancer and
Health cohort is a prospective cohort study [13]. At baseline
(between 1993 and 1997), men and women aged 50–64 years
and living in the counties of Copenhagen and Aarhus were
invited to participate, which 36% (n = 57,053) agreed to. At
the baseline visit, participants completed lifestyle- and dietary
questionnaires [14] and trained personnel conducted physical
examinations and blood sampling. The blood samples (30 ml)
were processed and frozen in liquid nitrogen vapour (−150°C)
within 2 h.
The 57,053 cohort participants were followed for incident
diabetes in the Danish Diabetes Registry from baseline until
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the end of 2009 [15]. Inclusion in the register was based on the
following diagnostic criteria: (1) registration in the National
Patient Register with a diagnosis of diabetes; (2) registration of
chiropody (as diabetic patient) in the Danish National Health
Service Register (NHSR); (3) five blood-glucose measurements
in a 1 year period in the Danish NHSR; (4) two blood-glucose
measurements per year for five consecutive years in NHSR; (5)
purchase of oral glucose-lowering drugs in the Danish National
Prescription Registry (DNPR) [16] and (6) purchase of pre-
scribed insulin recorded in DNPR. As criteria 3 and 4 have the
lowest positive predictive values [15], cohort participants regis-
tered with one of these criteria alone were not defined as ‘cases’.
The number of incident diabetes cases was 6177. Of these, 1526
were diagnosed based on criteria 3 or 4 only and therefore not
included; an additional 168 cases were excluded due to a lack of
plasma sample, resulting in 4483 eligible peoplewith diabetes. It
is not possible to distinguish between type 1 diabetes and type 2
diabetes cases based on the information available in the Danish
Diabetes Registry [15]. However, as the baseline age was 50+
and the median age at diagnosis 65 years, we assume that the
vast majority were diagnosed with type 2 diabetes and hereafter
refer to diabetes as type 2 diabetes.
Vital status was obtained through linkage to The Danish
Civil Registration System [17] and cause-specific death was
obtained from the Danish Register of Causes of Death [18].
Causes of death were grouped by the following ICD-10 code
categories (http://apps.who.int/classifications/icd10/browse/
2016/en): cardiovascular diseases (I-); cancer (C-); diabetes
(E10-14); respiratory diseases (J-) and other causes (including
infections) (A-, B-), accidents/suicides/assaults (V-, W-, X-,
Y-), renal failure (N-), mental disorders (F-), nervous system
disorders (G-), digestive disorders (K-), other endocrine dis-
orders (E-) and musculoskeletal diseases (M-). Mortality rate
ratio from all causes was the primary endpoint and cause-
specific mortality outcomes were secondary. For the present
study, information on vital status was available until 1
February 2016 whereas information on cause of death only
could be obtained until 31 December 2015. This leaves 13
deaths only included in the analyses of all-cause mortality.
In total, 1402 people among the population of 4483 diag-
nosed with type 2 diabetes died during the follow-up period
from date of diagnoses (before 31 December 2009) and end of
follow-up on 1 February 2016.
For the current study, a case-cohort design was applied [19].
A random subcohort of 850 individuals was sampled from the
4483 people in the study population. Of these, 268 died during
follow-up. Further, n = 450 cases from the 1402 deceased in-
dividuals with type 2 diabetes were randomly sampled. By
coincidence, 101 people with type 2 diabetes were already part
of the subcohort. Therefore, our study base consisted of a
subcohort of 850 individuals, including 268 deaths, and an
additional 349 cases (450 minus the 101 individuals overlap-
ping) included in the study according to the principles of the
case-cohort design (n = 617 deaths). Following exclusions
(missing information on covariates, no available sample or
failure enterolactone measurement), the final subcohort
consisted of 841 individuals and there were 610 deaths (268
within the subcohort + 342 additional cases). Causes of death
covered diabetes-specific death where diabetes as such was
registered as the underlying cause of death (n = 48), cardiovas-
cular diseases (n = 141), cancer (n = 243), respiratory diseases
(n = 63), other diseases (n = 102) or unknown causes (n = 13).
Laboratory analyses Enterolactone concentrations were deter-
mined using a liquid chromatography–tandem mass spec-
trometry (LC-MS/MS) method [20] wherein the intact form
of enterolactone was measured as glucuronide-conjugated,
sulphate-conjugated or free enterolactone. The sum of these
three forms constitutes the total enterolactone concentration.
Robustness of the enterolactone assay was validated both dur-
ing method development [20] and during sample analyses
using six quality-control samples in each batch. During meth-
od development, inter-batch variation was calculated to be
lower than 10%, which was similar during sample analyses.
Health score Because general health is a strong predictor of
mortality [21], we wanted to explore whether the association
between enterolactone and mortality could be explained by
enterolactone being a marker of general health. Therefore,
we created a score based on three health behaviours. BMI,
smoking status and physical (in)activity are known mortality
risk factors [21] and were chosen to best reflect general health
status based on the available baseline questionnaire informa-
tion. We expected that any association between enterolactone
and mortality would disappear in the health-score-stratified
analysis if enterolactone level was simply an indicator of gen-
eral health. The three factors were scored from 0 to 2 points,
with the highest score representing the healthiest behaviour as
follows: BMI ≤27 kg/m2 (score 2), 27–32 kg/m2 (score 1),
>32 kg/m2 (score 0); smoking status never (score 1), former
(score 0.5), current (score 0); participation in sport activities
yes (score 1), no (score 0). The total score ranged from 0 to 4
points and was further divided into a low (≤1.5), medium
(1.5–3.0) and high (≥3) category of healthy lifestyle.
Information on antibiotics Use of antibiotics is known to af-
fect enterolactone concentrations [22]. Therefore, information
about redeemed prescriptions for systemic antibiotics, within
12 months prior to baseline, was obtained from the DNPR
[16]. Antibiotic use was categorised in three groups based
on the most recent filling of prescriptions: 0–3 months before
baseline; 3–12months before baseline or no use (0–12months
before baseline). As the registry was established in 1995, only
participants with baseline from 1 January 1996 and onwards
could be registered in the database with sufficient information
to go 12 months back (n = 596, 50% of total).
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Ethics The study was approved by the regional ethical com-
mittees on human studies in Copenhagen and Aarhus [File
(KF)11-037/01] and by the Danish Data Protection Agency.
All study participants gave written informed consent. The
Danish authorities (Sundhedsdatastyrelsen) approved linkage
with the DNPR and these analyses were conducted through
Statistics Denmark.
Statistical methods The association between plasma
enterolactone concentrations and mortality was assessed in a
case-cohort design by Cox proportional hazard models with
cases outside the subcohort entering the risk set just before
their event time as suggested by Prentice [19] using robust
variance estimation [23]. The subcohort members contributed
with follow-up time from date of diagnosis to date of exit
(death, emigration or end of follow-up at 1 February 2016
for all-cause mortality and at 31 December 2015 for cause-
specific mortality) and time since diagnosis was used as the
underlying time scale. Initially, age in 5 year bands and sex
was included in strata to allow for different underlying haz-
ards. Linearity of the dose–response association for the main
exposure, plasma enterolactone concentration and the contin-
uous potential confounders were tested by linear splines.
According to this, enterolactone was log2 transformed to ob-
tain a linear association and BMI showing a U-shaped associ-
ation was categorised into three groups (≤27 kg/m2, 27–32 kg/
m2, >32 kg/m2). The remaining continuous potential con-
founders (alcohol intake, time between baseline and diagno-
sis, blood pressure, number of hours spent participating in
sports, bowel movements, smoking duration and intensity
and consumption of sugar-sweetened beverages, red meat
and processed meat) showed no deviations from linearity.
The proportional hazards assumption was assessed for the
main exposure variable and the confounders by correlation
tests of the Schoenfeld residuals as proposed by Xue et al
[24]. Smoking violated the proportional hazards assumption
(all p < 0.003) but after including it in strata together with age
and sex, none of the remaining variables violated the propor-
tional hazards assumption (all p ≥ 0.25).
Model 1, the crude model, was stratified in 5 year age
bands and by sex. Model 2 was additionally adjusted for
smoking and BMI, as both were considered important risk
factors and thus included a priori [21, 25]. In model 3, addi-
tional potential confounders were included based on an ap-
proach of >10% change in exposure coefficient estimate [26].
Based on this (>10%), sports participation (yes/no) and alco-
hol intake (alcohol abstain yes/no, intake among users, linear)
were included. Furthermore, time between baseline and diag-
nosis (linear), blood pressure (systolic and diastolic, mmHg),
time spent participating in sports (h/week), bowel movements
(no. of times/week), additional information on tobacco use
(smoking duration and intensity, no. of cigarettes per day or
year), consumption of sugar-sweetened beverages (g/day), red
meat (g/day) and processed meat (g/day), number of years of
schooling (≤7 years, 8–10 years, ≥11 years), hormone use
(never, former, current, male sex hormones) and menopausal
status (postmenopause/premenopause) were tested as poten-
tial confounders but were not included (change in β-estimate
<10%). No effect modification by age (p = 0.77), sex (p =
0.13) or menopausal status (p = 0.17) was observed.
Sensitivity analyses To investigate whether the association
between enterolactone concentration and all-cause mortality
was consistent across subgroups according to general health
status, we estimated the linear association between
enterolactone and mortality within each of the three health-
score categories (low, middle, high) in one model. Effect mod-
ification by health-score category was tested by combining
health-score category with quartile of enterolactone [27]. No
interaction between health-score category and enterolactone
quartile was observed (p = 0.77).
Further, a sensitivity analysis was conducted to investigate
whether use of antibiotic medication affected the association
between enterolactone concentration and mortality. This was
done by adding an antibiotic variable (0–3 months before
baseline, 3–12 months before baseline or no use [12 months
preceding baseline]) to the adjusted model for the subset of
participants (n = 596) for which information on antibiotic
medication was available. A separate analysis among non-
users of antibiotics (n = 430) was likewise conducted.
The statistical analyses were conducted in SAS statistical
software release 9.3 (SAS Institute, Cary, NC, USA).
Results
The case-cohort study population included 1183 individuals
diagnosed with type 2 diabetes, a randomly selected subcohort
of 841, and 342 deceased cases in the sampled deceased
group. The median age at type 2 diabetes diagnosis was
65 years (5th to 95th percentile 55–74), which was 7.4 years
(5th to 95th percentile 0.4–13.4) after blood sampling. Sixty
per cent were men and the median follow-up time was
10.7 years for the subcohort. During the follow-up time, 268
people from the subcohort died, resulting in 610 deaths when
combining deaths in the subcohort and the sampled deceased
group.
Among the subcohort of people diagnosed with type 2
diabetes, 60% were men, the median age at diagnosis was
64 years (5th to 95th percentile 54–74) and the follow-up time
for all-cause mortality was 10.7 years (5th to 95th percentile
1.8–18.5). At study baseline, median BMI was 28.8 kg/m2,
the proportion of current smokers was 41% and 43% engaged
in sports activity (Table 1). The entire Diet, Cancer and Health
cohort had a lower proportion of men (47%), current smokers
(36%), a lower median BMI (25.5 kg/m2) and a higher
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Table 1 Baseline characteristics by subcohort, and deceased by cause-specific mortality: a case-cohort study in the Diet, Cancer andHealth cohort (n =
1183)
Characteristic Subcohort Deceased
All
n = 841
All
n = 610
Diabetes
n = 48
Cardiovascular
n = 141
Cancer
n = 243
Respiratory
n = 63
Other
n = 102
Age at diagnosis, years 64 (54–74) 65 (55–75) 63 (53–74) 65 (56–75) 65 (56–74) 65 (57–73) 65 (54–76)
Follow-up timea, years 10.7 (1.8–18.5) 7.1 (0.2–15.7) 11.3 (0.8–18.4) 6.2 (0.08–13.8) 6.6 (0.1–15.0) 9.4 (2.6–17.0) 8.1 (0.3–15.1)
Pre-diagnostic (at study baseline)
Enterolactone, nmol/l 10.9 (1.3–59.6) 9.5 (1.1–49.7) 6.5 (1.3–22.1) 11.0 (1.2–43.4) 8.9 (1.1–49.8) 9.4 (1.3–62.5) 9.1 (1.1–43.2)
Male sex, n (%) 508 (60) 413 (68) 28 (58) 102 (72) 166 (68) 38 (60) 70 (69)
BMI, kg/m2 28.8 (22.8–37.6) 28.8 (22.1–40.8) 29.8 (24.2–41.5) 29.0 (23.4–42.1) 28.8 (21.9–37.8) 27.6 (20.1–38.2) 28.1 (21.8–36.1)
Height, cm 172 (157–184.5) 172 (157–184) 171 (154–184) 173 (158–184) 173 (157–185) 169 (156–183) 171 (160–186)
Waist circumference, cm 99 (77–121) 100 (77–126) 102 (83–130) 100 (83–131) 101 (77–122) 100 (72–123) 99 (76–125)
Systolic blood pressure, mmHg 146 (117–184) 151 (119–190) 160 (116–189) 155 (121–201) 147 (119–189) 147 (120–184) 152 (117–184)
Diastolic blood pressure, mmHg 87 (69–105) 88 (70–108) 90 (72–111) 89 (72–111) 88 (70–106) 86 (69–105) 89 (68–108)
Serum cholesterol, mmol/l 6.1 (4.3–8.2) 6.1 (4.2–8.5) 6.0 (3.9–8.5) 6.5 (4.3–8.7) 6.1 (4.3–8.3) 5.7 (3.8–7.6) 6.0 (4.4–8.1)
Whole-grain intake, g/day 37.6 (9.0–79.3) 37.2 (7.4–75.7) 38.0 (9.3–71.7) 39.3 (11.0–78.3) 37.1 (7.4–75.7) 37.7 (10.8–77.0) 31.0 (5.6–70.7)
Cabbage intake, g/day 13.2 (2.0–42.6) 11.1 (1.7–37.5) 14.4 (2.8–45.0) 10.7 (2.0–31.0) 11.0 (1.6–38.6) 10.1 (1.8–36.6) 11.2 (1.8–37.1)
Leafy vegetable intake, g/day 6.1 (0.5–34.0) 4.2 (0–26.4) 4.2 (0.5–35.1) 4.2 (0–22.6) 4.1 (0.3–34.7) 4.8 (0.4–26.0) 4.2 (0–25.5)
Red meat intake, g/day 88 (39–178) 87 (39–191) 83 (49–169) 88 (39–191) 88 (38–216) 81 (34–178) 87 (41–168)
Processed meat intake, g/day 30 (7–81) 34 (8–96) 35 (7–101) 34 (8–131) 35 (8–93) 28 (7–91) 32 (8–89)
Coffee consumption, no. of cups/day 4.5 (0.1–8) 4.5 (0–8) 4.5 (0–8) 4.5 (0.4–8) 4.5 (0–8) 4.5 (0–8) 4.5 (0–8)
Sugar-sweetened beverage consumption, g/day 20 (0–516) 20 (0–529) 16 (0–500) 29 (0–900) 20 (0–503) 32 (0–700) 20 (0–529)
Alcohol intake among users, g/day 13.7 (0.8–69.4) 16.1 (0.7–84.7) 11.8 (0.4–57.3) 14.3 (0.7–81.5) 16.0 (1.0–85.3) 12.6 (0.4–83.9) 20.3 (1.0–114.5)
Alcohol abstainers, n (%) 26 (3) 26 (4) 3 (6) 7 (5) 8 (3) 4 (6) 4 (4)
Bowel movements/week 4 (2–5) 4 (2–5) 4 (2–6) 4 (2–6) 4 (3–5) 4 (2–5) 4 (3–5)
Sport (yes), n (%) 359 (43) 186 (31) 13 (27) 43 (31) 71 (29) 14 (22) 38 (37)
Sport, h/week 1.5 (0.5–6.0) 2.0 (0.5–7.0) 1.5 (0.5–5.0) 1.5 (0.5–5.0) 2.0 (0.5–6.0) 1.5 (0.5–18.0) 2.0 (0.5–10.0)
School, n (%)
Low 351 (42) 299 (49) 22 (46) 74 (52) 106 (44) 38 (60) 53 (52)
Middle 372 (44) 247 (41) 21 (44) 46 (33) 115 (47) 22 (35) 36 (35)
High 118 (14) 64 (11) 5 (10) 21 (15) 22 (9) 3 (5) 13 (13)
Smoking status, n (%)
Never 230 (27) 122 (20) 11 (23) 27 (19) 50 (21) 8 (13) 23 (23)
Former 267 (32) 158 (26) 11 (23) 48 (34) 59 (24) 10 (16) 25 (25)
Current 344 (41) 330 (54) 26 (54) 66 (47) 134 (55) 45 (71) 54 (53)
Former and current smokers
Years of smoking, years 33 (8–47) 37 (10–48) 37 (15–46) 38 (3–49) 37 (10–47) 40 (23–48) 36 (10–48)
Pack-years, years 25.6 (2.5–60.8) 30 (3.5–67) 27.5 (5.8–51.5) 28.0 (1.5–82.9) 31 (3.5–71.0) 30.5 (12.5–76.5) 29.5 (1.5–55.8)
Current smokers
Tobacco, g/day 20 (5–67) 20 (5–40) 20 (5–40) 20 (5–37) 20 (5–44) 20 (10–34) 20 (3–30)
Menopausal hormone therapy in women, n (%)
Never 190 (57) 106 (54) 12 (60) 23 (59) 42 (55) 13 (52) 14 (44)
Former 62 (19) 43 (22) 6 (30) 7 (18) 16 (21) 4 (16) 9 (28)
Current 81 (24) 48 (24) 2 (10) 9 (23) 19 (25) 8 (32) 9 (28)
Menopausal state of women (post), n (%) 284 (85) 176 (89) 18 (90) 35 (90) 67 (87) 23 (92) 29 (91)
0–12 months before study baseline
Antibiotic medication, n (%)
Missing data (baseline before 1996) 389 (46) 336 (55) 27 (56) 90 (64) 113 (47) 40 (63) 60 (59)
Among the subgroup with information
(baseline 1996 and onwards), n (%)
452 274 21 51 130 23 42
No use (12 months preceding baseline) 328 (73) 193 (70) 15 (71) 38 (75) 89 (68) 15 (65) 31 (74)
0–3 months before baseline 43 (10) 32 (12) 6 (29)b 13 (25)b 41 (32)b 8 (35)b 11 (26)b
3–12 months before baseline 81 (18) 49 (18)
Baseline enterolactone, nmol/l
No antibiotic use (12 months before baseline) 11.8 (1.5–59.8) 10.2 (1.2–46.0) 6.7 (1.6–24.3) 11.0 (0.6–39.6) 9.9 (1.2–48.5) 13.8 (2.7–47.5) 12.2 (1.3–29.8)
Antibiotic use (0–12 months before baseline) 8.9 (1.0–59.2) 10.1 (1.0–67.0) 8.7 (2.1–11.3) 9.9 (0.9–34.1) 10.6 (0.8–82.4) 9.6 (2.4–32.0) 6.6 (1.9–67.0)
Data are shown as median (5th–95th percentile) or n (%)
a Time between diagnosis and exit, only subcohort (n = 841)
b Due to the low number of participants, the groups 0–3 and 3–12 months before baseline were grouped together
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participation in sports (54%) [13] compared with the sub-
group of people with diabetes included in the current study.
Median enterolactone concentrations measured for previously
published studies (n = 2237) were 21.3 nmol/l for women and
18.6 nmol/l for men [9]. Pre-diagnostic baseline characteris-
tics are presented by quartile of enterolactone concentrations
for the subcohort only (Table 2), and according to group
(subcohort and deceased). The deceased group was further
subdivided according to cause of death (Table 1).
Overall, the plasma enterolactone concentrations measured
in blood samples from baseline were low, with a median of
10.9 nmol/l (5th to 95th percentile 1.3–59.6) in the subcohort
(Table 1). The concentrations varied by cause of death, with
the lowest enterolactone concentrations observed among
those who died from type 2 diabetes (6.5 nmol/l, 5th to 95th
percentile 1.3–22.1).
Higher pre-diagnostic plasma enterolactone concentra-
tions, assessed linearly per doubling in concentration (log2),
were associated with lower all-cause mortality (HRmodel2 0.91
[95% CI 0.85, 0.96]) (Table 3). When deaths were further
subdivided according to cause, the HRmodel2 for diabetes mor-
tality was 0.75 (95% CI 0.64, 0.86; based on 48 deaths due to
diabetes). The HRmodel2 was also assessed by quartiles of
enterolactone concentration; all-cause mortality was 37%
lower (HR 0.63 [95% CI 0.48, 0.84]) and diabetes mortality
was 78% lower (HR 0.22 [95% CI 0.07, 0.65]) for people in
the highest quartile comparedwith those in the lowest quartile.
For the remaining causes of death, results pointed towards
lower mortality with higher enterolactone levels but none of
the estimates reached statistical significance (Fig. 1).
Additional adjustment for sports participation and alcohol in-
take (Model 3) revealed similar results.
If enterolactone is a marker of general health rather than
being causally related, we suspected that stratifying by health
status would attenuate the association between enterolactone
and mortality. The inverse association observed in the strati-
fied analysis seemed apparent across all three health-score
categories (Table 4). Finally, antibiotic use did not alter the
association between enterolactone and mortality in the sub-
group for whom we were able to account for antibiotics (elec-
tronic supplementary material [ESM] ESM Table 1).
Sensitivity analyses were performed showing similar associa-
tions in the subgroup that did not use antibiotics in the
12 months before baseline.
Discussion
In this population-based case-cohort study to examine the as-
sociation between pre-diagnostic enterolactone concentrations
and mortality among individuals diagnosed with type 2 dia-
betes, we found that high concentrations were associated with
lower mortality. We observed a borderline significant
association for all-cause mortality and markedly lower HRs
for diabetes-specific mortality, although the latter was based
on a limited number of cases. For the quartile estimates of all-
cause mortality, there seemed to be a threshold effect whereby
individuals in the second to fourth quartile had a 26–39%
lower risk compared with the lowest quartile. For diabetes-
specific mortality, a dose–response relationship with lower
HRs by higher quartile of enterolactone was observed.
Similar associations were observed across health-score cate-
gories; additional adjustments resulted in similar estimates,
suggesting that enterolactone is not merely a marker of general
health. There was no association between enterolactone and
other cause-specific mortality outcomes.
The case-cohort design of the present study has the advan-
tage of combining the temporal design of the large prospective
study and the case−control design, allowing for an
oversampling of cases (the sampled deceased group) to in-
crease study power. Furthermore, detailed information on
baseline lifestyle behaviour enabled thorough adjustment for
potential confounders. Enterolactone was measured in blood
samples taken before the participants were diagnosed with
type 2 diabetes and thus the concentrations can be assumed
to be unaffected by disease status. The metabolism of lignans
into enterolignans (enterodiol and enterolactone) is affected
by several factors including smoking and obesity [6].
Another important factor for the conversion of dietary lignans
to enterolactone is the microbiota. The final conversion from
enterodiol to enterolactone is known to be carried out by niche
groups of microorganisms [28] and can be affected by antibi-
otic medication for over a year following administration [9].
We were able to adjust for that through linkage to the DNPR.
However, the findings in the present study deviated from
existing evidence (i.e. antibiotics did not affect the results).
Case ascertainment, vital status and cause of death were ob-
tained from Danish registries, which are known to be of high
quality [29] as they contain nearly complete information
through the personal identification number of all people living
in Denmark.
The study also has some weaknesses to consider when
interpreting the results. The Cause of Death Registry relies on
the correctness of the physicians’ information and the coding in
theNational Board ofHealth. Autopsies are performed rarely and
therefore uncertainty of the causes of deaths exists [18].
However, overall mortality was the primary outcome in this
study and information on vital status was complete and unaffect-
ed by potential misclassification of underlying cause of death.
Cause-specificmortalitywas a secondary outcome butwas based
solely on the correctness of the Causes of Death Registry. The
median time between blood sampling and diabetes diagnosis was
7.4 years and some participants might have changed dietary
habits or other lifestyle behaviours affecting enterolactone con-
centrations, disease risk and perhaps prognosis during this peri-
od. Our results can consequently not be used to make direct
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conclusions on dietary changes among people already diagnosed
with diabetes. On the contrary, exposure measurements
conducted close to the time of diagnosis increase the risk of
reverse causality. Repeated measurements of enterolactone
Table 2 Baseline characteristics of subcohort by quartile of enterolactone concentration of individuals with type 2 diabetes: a case-cohort study in the
Diet, Cancer and Health cohort (n = 841)
Characteristic 1st quartile
(0–5.42 nmol/l)
n = 210
2nd quartile
(5.45–10.89 nmol/l)
n = 210
3rd quartile
(10.92–22.54 nmol/l)
n = 211
4th quartile
(22.88–296.30 nmol/l)
n = 210
Age at diagnosis, years 64 (54–73) 65 (54–75) 64 (55–74) 64 (55–74)
Follow-up timea, years 10.5 (2.4–18.5) 10.5 (0.7–18.1) 10.7 (2.2–18.5) 10.7 (2.3–18.7)
Deceased, n (%) 83 (40) 67 (32) 61 (29) 57 (27)
Pre-diagnostic (at study baseline)
Enterolactone concentration, nmol/l 2.92 (0.64–5.14) 7.75 (5.66–10.28) 15.78 (11.26–21.91) 38.29 (23.90–110.53)
Male sex, n (%) 131 (62) 145 (69) 123 (58) 109 (52)
BMI, kg/m2 29.3 (22.8–37.6) 28.6 (23.3–37.5) 29.4 (23.9–37.5) 28.4 (22.1–37.8)
Height, cm 172 (159–184) 172 (157–184) 172 (156–186) 171 (157–186)
Waist circumference, cm 100 (78–123) 100 (77–120) 100 (77–121) 96 (75–120)
Systolic blood pressure, mmHg 148 (117–186) 146 (119–182) 146 (119–185) 146 (112–183)
Diastolic blood pressure, mmHg 88 (70–118) 87 (72–104) 87 (68–105) 87 (69–103)
Serum cholesterol, mmol/l 6.0 (4.0–8.3) 6.2 (4.5–8.2) 6.1 (4.3–8.3) 6.2 (4.4–8.1)
Whole-grain intake, g/day 31.7 (6.7–79.4) 37.8 (9.4–74.3) 38.2 (11.2–81.3) 39.5 (17.1–80.9)
Cabbage intake, g/day 10.4 (1.6–38.6) 11.7 (2.3–40.5) 15.7 (3.0–41.3) 14.9 (1.9–46.4)
Leafy vegetable intake, g/day 4.0 (0.4–33.8) 4.7 (0.2–29.9) 7.6 (1.2–36.6) 7.4 (0.6–36.0)
Red meat intake, g/day 93 (42–184) 90 (39–192) 90 (36–166) 82 (35–169)
Processed meat intake, g/day 32 (8–93) 33 (7–85) 29 (7–85) 25 (6–69)
Coffee consumption, no. of cups/day 4.5 (0–8) 4.5 (0.4–8) 4.5 (0.1–8) 4.5 (0–8)
Sugar-sweetened beverage consumption, g/day 29 (0–516) 30 (0–516) 20 (0–286) 16 (0–503)
Bowel movements/week 4 (3–6) 4 (2–5) 4 (2–5) 4 (2–5)
Alcohol intake, g/day 15.3 (1.0–80.3) 14.8 (0.6–68.9) 14.7 (1.2–67.5) 12.4 (0.8–63.6)
Abstainers, n (%) 6 (3) 10 (5) 6 (3) 4 (2)
Sport (yes), n (%) 62 (30) 84 (40) 106 (50) 107 (51)
Sport, h/week 2.0 (0.5–6.0) 1.5 (0.5–6.0) 1.5 (0.5–7.0) 1.5 (0.5–4.0)
School, n (%)
Low 97 (46) 85 (40) 84 (40) 85 (40)
Middle 90 (43) 95 (45) 96 (45) 91 (43)
High 23 (11) 30 (14) 31 (15) 34 (16)
Smoking status, n (%)
Never 54 (26) 41 (20) 69 (33) 66 (31)
Former 50 (24) 69 (33) 71 (34) 77 (37)
Current 106 (50) 100 (48) 71 (34) 67 (32)
Former and current smokers
Years of smoking, years 35 (12–46) 34 (8–49) 32 (6–48) 30 (9–45)
Pack-years, years 29 (5–66) 26 (3–59) 24 (2–67) 22 (1–56)
Current smokers
Tobacco, g/day 20 (10–40) 18 (6–36) 20 (4–45) 18 (2–32)
Menopausal hormone therapy in women, n (%)
Never 43 (54) 43 (66) 47 (53) 57 (56)
Former 9 (11) 11 (17) 20 (23) 22 (22)
Current 27 (34) 11 (17) 21 (24) 22 (22)
Menopausal state in women (post), n (%) 71 (90) 57 (88) 74 (84) 82 (81)
0–12 months before study baseline
Antibiotic medication, n (%)
Missing (baseline before 1996) 97 (46) 98 (47) 100 (47) 94 (45)
Among the subgroup with information,
n (baseline 1996 and onwards), %
113 112 111 116
No use (12 months preceding baseline) 75 (66) 83 (74) 86 (77) 84 (72)
0–3 months and 3–12 months before baselineb 38 (34) 29 (26) 25 (23) 32 (28)
Baseline enterolactone, nmol/l
No antibiotic use (12 months before baseline) 2.9 (0.7–5.2) 8.2 (5.6–10.5) 15.2 (11.6–21.6) 36.7 (24.1–96.1)
Antibiotic use (0–12 months before baseline) 2.4 (0.5–5.1) 7.0 (5.6–10.1) 15.8 (11.3–20.2) 42.0 (23.6–83.0)
Data are shown as median (5th–95th percentile) or n (%)
a Time between diagnosis and exit, only subcohort (n = 841)
b Due to the low number of participants, the groups 0–3 and 3–12 months before baseline were grouped together
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concentrations at different points in disease development would
have been a study strength but were not conducted. Reassuringly
though, repeated samples in a recent breast cancer study based on
the same cohort showed good agreement between baseline and
diagnostic enterolactone concentrations [30]. Another factor con-
tributing to management and prognosis of type 2 diabetes is the
stage of disease, which is possibly reflected by medication and
degree of complications.We could have obtained information on
medication use but the interpretation of the results are not
straightforward. Medication use may both be a proxy of an ad-
vanced disease and a well-managed disease.
The participants in the Danish Diet, Cancer and Health
cohort had higher socioeconomic position than non-
participants [13] and this may impact the generalisability of
Table 3 HR (95% CI) for pre-diagnostic plasma enterolactone concentrations and all-cause and cause-specific mortality among individuals diagnosed
with type 2 diabetes: a case-cohort study based on the Diet, Cancer and Health cohort
Model All causes
n = 610
Diabetes
n = 48
Cardiovascular
n = 141
Cancer
n = 243
Respiratory
n = 63
Other
n = 102
Model 1a 0.88 (0.83, 0.93) 0.72 (0.62, 0.83) 0.92 (0.82, 1.03) 0.88 (0.81, 0.95) 0.89 (0.77, 1.03) 0.88 (0.78, 0.99)
Model 2b 0.91 (0.85, 0.96) 0.75 (0.64, 0.86) 0.94 (0.84, 1.05) 0.91 (0.84, 1.00) 0.95 (0.82, 1.11) 0.90 (0.80, 1.01)
Model 3c 0.94 (0.88, 1.00) 0.76 (0.65, 0.88) 0.97 (0.86, 1.09) 0.95 (0.87, 1.03) 0.98 (0.84, 1.15) 0.94 (0.83, 1.07)
Data are presented as HR (95% CI), linear, by doubling in enterolactone concentration (log2)
a Adjusted for sex, age (5 year bands)
b Adjusted for sex, age (5 year bands), smoking (never, former, current), BMI status (<27, 27–32, >32 kg/m2 )
c Adjusted for sex, age (5 year bands), smoking (never, former, current), BMI status (<27, 27–32, >32 kg/m2 ), sports participation (yes/no), alcohol
intake (alcohol abstain yes/no, intake among users, linear)
24/296
23/296
23/296
32/295
14/296
15/296
15/296
19/295
53/296
58/296
54/296
78/295
30/296
46/296
30/296
35/295
4/296
10/296
17/296
17/295
129/296
155/296
144/296
182/295
Deaths/Total
1.81.20.80.40.2
0.64 (0.37, 1.11)
0.59 (0.33, 1.07)
0.53 (0.30, 0.94)
1.00 (ref.)
0.64 (0.32, 1.30)
0.72 (0.36, 1.43)
0.55 (0.26, 1.16)
1.00 (ref.)
0.64 (0.43, 0.93)
0.68 (0.46, 1.00)
0.56 (0.38, 0.81)
1.00 (ref.)
0.75 (0.46, 1.24)
1.17 (0.72, 1.89)
0.69 (0.41, 1.16)
1.00 (ref.)
0.22 (0.07, 0.65)
0.45 (0.20, 1.06)
0.88 (0.42, 1.85)
1.00 (ref.)
0.63 (0.48, 0.84)
0.74 (0.56, 0.98)
0.61 (0.46, 0.80)
1.00 (ref.)
HR (95% CI)Mortality
All-cause
Diabetes
Cardiovascular
Cancer
Respiratory
Other
Enterolactone
Q4
Q3
Q2
Q1
Q4
Q3
Q2
Q1
Q4
Q3
Q2
Q1
Q4
Q3
Q2
Q1
Q4
Q3
Q2
Q1
Q4
Q3
Q2
Q1
Fig. 1 Forest plot of quartiles
(Q1–Q4) of enterolactone
concentration plotted on
logarithmic scale (log2)
associated with cause of death
adjusted for sex, age (5 year
bands), smoking and BMI among
individuals with type 2 diabetes in
a case-cohort study based on the
Danish Diet, Cancer and Health
cohort
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the findings. The median plasma enterolactone concentration
of 10.9 nmol/l (5th–95th percentile 1.3–59.6) was unexpect-
edly low compared with previous data from the same cohort
(20 nmol/l [5th–95th percentile 3–90] for women and
18.6 nmol/l [5th–95th percentile 3–87] for men) [9]. In these
earlier studies, the upper cut-off for the lowest enterolactone
quartile was around 10 nmol/l, which is approximately the
same as the upper limit of the second quartile in the present
study. Since we used the same analytical method in the pres-
ent study as in previously published studies on cancer cases
from the same cohort [9], we were able to perform a valida-
tion on overlapping samples, confirming that type 2 diabetes
cases had considerably low enterolactone concentrations
compared with cancer cases from the same study population.
A plausible explanation for this discrepancy could be the
observed changes in the microbiota of people with diabetes,
characterised by lower levels of clostridia [31] and
bifidobacteria [32]. Both of these bacteria are involved in
the deglycosylation step of the metabolism of lignans to
enterolactone [28, 33]. This could possibly lead to problems
of reverse causation, if the low enterolactone concentrations
were caused by diabetes development-induced microbial
changes. However, despite the low concentrations, we did
observe an association between enterolactone and mortality.
Another issue relates to the potential selection of people with
low enterolactone concentrations into the study population.
This is known as the ‘obesity paradox’ and is always rele-
vant to consider in prognostic study designs [34]. One can
speculate whether those being diagnosed with diabetes, de-
spite high enterolactone concentrations, are genetically
predisposed to developing a more aggressive type where
lifestyle factors have less impact on progression. When we
stratified on health status (BMI, smoking and physical activ-
ity) the associations were similar across health-status groups,
weakening the concern that differences in lifestyle explain
the observed association.
Risk factors related to mortality among people with type 2
diabetes in the USA include older age, male sex, lower in-
come, smoking and higher LDL-cholesterol levels [3]. In a
meta-analysis of intervention studies, both lignan-rich flax-
seeds and lignan supplements were associated with reduced
LDL-cholesterol level, possibly caused by increased
enterolactone concentrations [5]. The most important dietary
factors related to diabetes mortality include high intake of
processed meats and sugar-sweetened beverages and low in-
take of whole grains [1]. In Denmark, whole grains are the
most important source of plant lignans [35] and are generally
linked to intake of dietary fibre and other associated phyto-
chemicals [36] while smoking has previously been associated
with lower enterolactone concentrations [37]. The significant
association observed for diabetes-specific mortality is not like-
ly explained by enterolactone itself, but rather indicates that
people with type 2 diabetes dying from their disease as such
generally have poorly managed diabetes and poor overall
health reflected in low enterolactone concentrations. Our re-
sults suggest that people diagnosed with type 2 diabetes have
better prognosis related to high enterolactone concentrations.
High enterolactone concentrations can be obtained from in-
take of lignan-rich foods. In a dietary intervention with whole-
grain rye (high lignan) vs refined wheat (low lignan), plasma
enterolactone concentration was increased by 12 nmol/l fol-
lowing the high-lignan diet [38], a difference similar to that
between quartile 1 and quartile 3 in the current study. Further,
accumulating evidence supports the notion that dietary fibre
elicits beneficial effects on variables of diabetes management
[39], and high intakes of whole grains, fruit, vegetables, le-
gumes and nuts (good sources of lignans) have been linked to
improved glycaemic control and blood lipids in people with
type 2 diabetes [40]. Taken together, this emphasises the im-
portance of promoting a diet high in dietary fibre and lignans
(e.g. including whole grains and vegetables) for the manage-
ment of type 2 diabetes.
Table 4 HR (95% CI) for pre-
diagnostic enterolactone concen-
trations and all-cause mortality by
health-score category in people
with type 2 diabetes: a case-
cohort study based on the Diet,
Cancer and Health cohort
Variable Health score
Low Middle High
Individuals, n 483 443 257
Deaths, n 284 222 104
Quartile of enterolactone concentration
Q1 (0–4.97 nmol/l) 1.00 (ref) 0.65 (0.42, 0.99) 0.47 (0.25, 0.87)
Q2 (4.98–10.27 nmol/l) 0.52 (0.35, 0.78) 0.49 (0.31, 0.76) 0.38 (0.22, 0.64)
Q3 (10.28–21.54 nmol/l) 0.63 (0.42, 0.95) 0.60 (0.39, 0.93) 0.35 (0.21, 0.57)
Q4 (21.55–296.30 nmol/l) 0.66 (0.43, 1.01) 0.39 (0.25, 0.60) 0.33 (0.20, 0.55)
Linear, by doubling in enterolactone
concentration (log2)
0.92 (0.86, 0.99) 0.89 (0.82, 0.96) 0.91 (0.81, 1.02)
Adjusted for sex, age (5 year bands), alcohol intake (alcohol abstain yes/no, intake among users, linear)
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Conclusion Based on data from the Diet, Cancer and Health
cohort study, pre-diagnostic enterolactone concentrations were
inversely associated with all-cause and diabetes-specific mortal-
ity. Adjustment for antibiotic medication use did not attenuate the
results and there were no signs of effect modification by health
behaviour—although we still cannot rule out the possibility that
enterolactone is a marker of general health. Seemingly, no pub-
lished studies have so far reported on enterolactone and type 2
diabetes mortality. Therefore, our findings are novel but further
exploration of the potential role of enterolactone in type 2 diabe-
tes management is required.
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